COMMUNIQUÉS West-GlobeNewswire

Fortrea Announces Date for Fourth Quarter and Full Year 2025 Financial Results and Conference Call
29/01/2026
DURHAM, N.C., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its fourth quarter and full year 2025 [...]
SeaStar Medical to Present at Upcoming Noble Capital Markets Emerging Growth Virtual Equity Conference
29/01/2026
DENVER, Jan. 29, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and [...]
The International Myeloma Foundation Welcomes Dr. Stephen L. Houff to the IMF Board of Directors
29/01/2026
STUDIO CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today welcomed Stephen L. Houff, MD, as the newest member of the IMF Board of Directors. After going to medical school at [...]
INVO Fertility Enters into $7.5 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
29/01/2026
SARASOTA, Fla., Jan. 29, 2026 (GLOBE NEWSWIRE) -- INVO Fertility Inc. (“INVO” or the “Company”) (NASDAQ: IVF), a healthcare company focused on the fertility market, today announced it has entered into a warrant [...]
Applied Therapeutics Shares Letter to Stockholders Recommending Tender of Shares Following Offer Expiration Extension
29/01/2026
NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company” or “Applied”), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare [...]
CS Group (OTCQB: CSDX) Secures Strategic Manufacturing Partnerships, Accelerating Global Commercial Launch of MEDUSA SDP Hygiene Products
29/01/2026
CHEYENNE, Wyo., Jan. 29, 2026 (GLOBE NEWSWIRE) -- CS Diagnostics Corp. (OTCQB: CSDX), a medical technology and hygiene solutions company, today announced the confirmation of strategic manufacturing partnerships with [...]
Certara to Report Fourth Quarter and Full Year 2025 Financial Results on February 26th, 2025
29/01/2026
RADNOR, Pa., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth quarter and full [...]
Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan
29/01/2026
Approximately 50% reduction in target lesion and greater than 90% decrease in CA-125 observed in endometrial cancer patient The unconfirmed partial response (uPR) that was observed in the first scan has been achieved at [...]
Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board
29/01/2026
Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn’s disease, and late-stage clinical trial design Appointments strengthen Palisade Bio’s clinical [...]
CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026
29/01/2026
BERKELEY HEIGHTS, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases [...]
Glucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM Platform
29/01/2026
RUTHERFORD, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc.(“Glucotrack”, or the “Company”) (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel [...]
Immutep Quarterly Activities Report Q2 FY26
29/01/2026
Media Release Entered into strategic collaboration with Dr. Reddy’s for commercialisation of eftilagimod alfa (efti) in all countries outside North America, Europe, Japan, and Greater China In January 2026, Immutep [...]
YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy
29/01/2026
TAIWAN, Jan. 29, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations [...]
Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules
29/01/2026
DOYLESTOWN, Pa., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific [...]
Breakthru Medicine emerges from stealth with $60M Series A for cancer drug development
29/01/2026
PHOENIX, Ariz., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Breakthru Medicine emerges from stealth with the close of a $60M Series A financing round following a prior undisclosed seed round. Breakthru was founded by biotech [...]
NetraMark Strengthens Board Of Directors
29/01/2026
TORONTO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) , a premier artificial intelligence (AI) company transforming clinical trials [...]
Cibolo Health Designates HeartSciences’ MyoVista Insights™ as Endorsed ECG Management Platform for Network of 123 Independent Hospitals
29/01/2026
Southlake, TX, Jan. 29, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography [...]
Fedora Pharmaceuticals Highlights Efficacy of Novel Antibiotic, FPI-2119, against Antimicrobial-resistant Gram-negative Bacteria at the 2026 IMARI Conference
29/01/2026
FPI-2119 offers potential solution to multi-drug-resistant Gram-negative infections EDMONTON, Alberta , Jan. 29, 2026 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc., a leader in the development of drugs to treat [...]
OMEICOS Therapeutics Announces Positive Phase 2 Study Outcome Demonstrating OMT-28’s Potential in Primary Mitochondrial Diseases (PMD)
29/01/2026
Trial Results Support Transition into Late-Stage Development with Program Expected to be Phase 2b/3-ready in H2 2026 BERLIN, GERMANY, January 29, 2026 – OMEICOS, a clinical-stage biopharmaceutical company developing [...]

Pages